Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denikitug with or without nivolumab or chemotherapy in HER2-negative metastatic gastric/GEJ/esophageal adenocarcinoma
2025-524095-27-00Phase 2Authorised
- Sponsor
- Gilead Sciences
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of denikitug in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (3 arms), sponsored by Gilead Sciences. Primary endpoint: Objective response rate (ORR). Planned start Jul 2026; status: authorised.
02
Drugs
denikitug
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2025-524095-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524095-27-00.